Phase I, Single Centre, Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD3043 - AZD3043

Study identifier:D0510C00005

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

Phase I, Single Centre, Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous AZD3043 after a Single Ascending Bolus Dose Followed by a Single Infusion Dose in Elderly (=65 years) Healthy Volunteers

Medical condition

Safety, sedation

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD3043

Sex

All

Actual Enrollment

Study type

Interventional

Age

65 Years - 80 Years

Date

Study Start Date: 01 Mar 2010

Estimated Primary Completion Date: 01 Apr 2010

Estimated Study Completion Date: 01 Apr 2010

Study design

Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Basic Science

Verification:

Verified 01 Dec 2012 by AstraZeneca

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions
Experimental: 1	Drug: AZD3043 single dose/IV, bolus over 60secs - infusion over 30 mins

Documents available

Trial Results Summaries
Available here

Contacts

Investigators

Principal Investigator

Darren Wilbraham

Quintiles Drug Research Unit at Guy's HospitalQuintiles Ltd6 Newcomen StreetLondonSE1 1YRUnited Kingdom